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Prostaglandins: Critical roles in pregnancy and colon cancer
Philip W. Majerus
Cyclooxygenase catalyses a key step in prostaglandin
biosynthesis, and recent work suggests that one
isoenzyme, COX-2, has important roles in early stages
of pregnancy; it also appears to be involved in the
somewhat analogous process of colon tumor formation
and spread.
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Prostaglandins are best known as mediators of inflamma-
tion and hemostasis, hence the popular use of aspirin in
the control of pain and inflammation, and as an
antithrombotic agent. Prostaglandins are oxygenated
derivatives of arachidonic acid, a fatty acid that does not
naturally occur free inside cells. Together with other
arachidonic acid derivatives — a group collectively
known as icosanoids — prostaglandins are produced only
when cells are stimulated by agonists such as hormones,
cytokines, growth factors and neurotransmitters [1]. Ago-
nists that stimulate prostaglandin production do so by
binding to cell-surface receptors, triggering the activation
of cellular phospholipases that catalyse the hydrolysis of
specific membrane phospholipids, releasing free arachi-
donic acid. The liberated arachidonic acid is oxygenated
by the enzyme cyclooxygenase to form prostaglandin H2
(PGH2), the precursor of all prostaglandins (Figure 1).
The end products act as hormone-like signalling mole-
cules through G-protein-coupled receptors to control
physiological processes such as vascular tone, salt and
water balance, gastric acid secretion and platelet activa-
tion. Recent studies with knockout mice have now pro-
vided evidence that prostaglandins actually have much
broader roles than previously thought, controlling
complex processes such as pregnancy.
Two distinct cyclooxygenase isoenzymes are known,
encoded by different genes and designated COX-1 and
COX-2 [1]. COX-1 is produced constitutively by most
cells, and so is primarily responsible for the immediate
synthesis of prostaglandins in response to agonist stimula-
tion. COX-2, in contrast, is made only in response to
agonists, such as inflammatory cytokines, so the
prostaglandin synthesis that it catalyses occurs several
hours after stimulation. COX-2 turns over rapidly, and
transcription of its gene is subject to complex control by
the intracellular signalling molecules cyclic (c)AMP,
tyrosine kinases and protein kinase C.
Cyclooxygenase inhibitors — the so-called non-steroidal
anti-inflammatory drugs (NSAIDs) — are an important
group of drugs in the treatment of inflammation. These
drugs differ in their selectivity for COX-1 versus COX-2,
although all of the currently marketed drugs preferentially
inhibit COX-1. Several COX-2-selective inhibitors are
now in development, as it is thought that COX-2 is more
important in inflammation than COX-1. The major toxic
side-effects of current NSAIDs are bleeding and gastritis,
both of which are thought to result from COX-1
inhibition. Selective COX-2 inhibitors may thus turn out
to be efficient anti-inflammatory agents with relatively
low toxicity.
The results of numerous studies indicate that COX-1 and
COX-2 have discrete functions. Much has recently been
learned about these enzymes from a series of gene knock-
out experiments in mice. The COX-1 knockout mouse has
a mild phenotype, with decreased platelet function — this
Figure 1
The cyclooxygenase pathway. Extracellular agonists bind to cell-
surface receptors and thereby activate phospholipases that liberate
arachidonate from membrane phospholipids. Cyclooxygenase, either
COX-1 or COX-2, then catalyses the formation of prostaglandin H2
(PGH2). Other enzymes then form the specific products prostaglandin
D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α),
prostacyclin (PGI2) and thromboxane A2 (TXA2).
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is not surprising, as platelets express only COX-1 [2]. The
COX-1 mutants are fertile, but homozygous matings tend
to yield dead pups for unknown reasons. COX-2 knockout
mice, in contrast, succumb to a nephropathy at about eight
weeks of age, and the females are sterile [3]. The basis for
the female sterility has been elucidated in a recent study
[4] that explored the role of COX-2 in the early stages of
pregnancy. COX-2 was found to be important for each
stage of pregnancy examined.
The female wild-type mice used by Lim et al. [4] pro-
duced seven ova per cycle and when mated, two-thirds of
the ova were fertilised. Female COX-2 mutants, in con-
trast, produced just three ova per cycle, and none of these
was fertilised when mating was attempted. The ova pro-
duced by the COX-2 mutants were abnormal in that the
first polar body was not extruded in most cases. These
defects were not due to a deficiency of pituitary or
ovarian hormones, as the same defects were observed
when females were subjected to superovulation with
exogenous gonadotropins. 
Further experiments showed that blastocyst implantation
is also defective in COX-2 mutant mice [4]. After intra-
uterine injection of blastocysts into pseudopregnant
females, implantation was observed in one-half of the wild-
type mice but in only 1% of the COX-2 mutants. Controls
using ovariectomised mice treated with progesterone and
oestrogen showed that the defect does not result from
inadequate hormones. Implantation was found to be
normal in COX-1 mutant mice; when COX-1 mutants were
treated with high doses of a selective COX-2 inhibitor,
however, there was complete failure of implantation.
Implantation was also inhibited in wild-type mice by high
doses of the selective COX-2 inhibitor, but not in those
given aspirin at a dose that primarily inhibits COX-1. 
Lim et al. [4] also studied the formation of the specialised
uterine lining required to support embryos, a process known
as decidualisation. They used an assay in which oil was
infused into the uterus during pseudopregnancy: by day
eight, the uterus of wild-type mice increased 15-fold in
weight, but the COX-2 mutants showed no change in uterine
weight. Although these effects appear to be due to the
absence of a product of COX-2 in the mutant mice, infusion
of PGE2 or a stabile analogue of prostacyclin did not restore
decidualisation in pseudopregnant COX-2 mutant mice.
Perhaps the timing or dose of the exogenously supplied
prostaglandin was incorrect, or perhaps another, as yet
unknown, icosanoid product of COX-2 is required.
The pattern and timing of COX-2 expression also supports
the view that its product has a role in pregnancy. Injection
of rats with gonadotropin results in transient COX-2
expression in granulosa cells prior to ovulation [5].
Immunohistochemistry of ova on days one and two of
pregnancy showed strong COX-2 expression in the
cumulus cells that surround the ovum and are required for
development of fertilisation-competent eggs [4]. There
was no uterine COX-2 expression on day four of pseudo-
pregnancy until oil injection into the uterine horn; this
caused a marked increase in COX-2 expression at two
hours that was gone by eight hours with no change in
COX-1 expression. Immunohistochemistry indicated that
COX-2 expression was greatest in cells directly adjacent to
the implanted blastocyst.
COX-2 products thus appear to be required for every step
of early pregnancy, including ovulation, fertilisation,
implantation and decidualisation. The particular
prostaglandins that are involved in these processes, and
the detailed ways that they act, remain to be determined.
The results suggest that potent, selective COX-2
inhibitors may interfere with pregnancy in humans. In
some cases this effect will be undesirable, but the possi-
bility that these agents might provide a safe and non-toxic
‘morning after pill’ is intriguing. 
An even more intriguing consideration comes from the
similarity between the early events of pregnancy and those
of tumor spread and metastasis. In both cases, cells must
escape from their original environment and implant at a
new site where a new vasculature must develop. Several
retrospective studies of aspirin use in man suggest that
COX inhibitors alter the natural history of colon cancer [6].
The risk of disease appears to be reduced in subjects who
take aspirin regularly for years. More surprisingly, the risk
of fatal or metastatic colon cancer appears to be reduced by
50% in chronic aspirin users. This may result from COX-2
inhibition, as most colon tumors and tumor cell lines
express high levels of COX-2, so products of this enzyme
may be important in tumor formation and metastasis [7].
And sulindac, a relatively non-selective COX inhibitor, has
been shown to decrease the development of intestinal
polyps in patients with familial polyposis [8]. 
Here again, knockout mice have been informative. Mice
in which the tumor suppressor gene adenomatous polyposis
coli (APC) has been inactivated develop polyps in large
numbers by 10 weeks of age. Recently, APC, COX-2
double mutant mice were bred by mating COX-2 mutant
mice to the APC mutants [9]. The double mutants
showed an 85% decrease in polyp production, compared
with the single APC mutants, directly demonstrating a
role for COX-2 in tumorigenesis. It would be interesting
to treat these animals with a COX-1 inhibitor to see if
tumor development can be further suppressed. Trials of
COX-2 inhibitors in patients with familial polyposis are
currently under way, and the results should be available
soon. It seems likely that these agents will affect the
natural history of the disease, given the results of studies
using sulindac [8]. 
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